Search | IOVS | ARVO Journals

Showing 1 – 20 of 30

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2020

EYS606 for the Treatment of Chronic Non-Infectious Uveitis (NIU): Results from Part 1 of a First-in-Human (EYS606-CT1) study

Ronald BUGGAGE; Francine F Behar-Cohen

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3170. doi:

ARVO Annual Meeting Abstract July 2019

Repeated plasmid electrotransfection into the ciliary muscle allows for fine-tuning of intraocular protein levels

Thierry Bordet; Karine Bigot; Elodie Touchard; Romain Benard; Jean-Denis Laffitte; Ronald BUGGAGE; Francine F Behar-Cohen

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2913. doi:

ARVO Annual Meeting Abstract July 2019

A promising non-viral gene therapy approach for retinitis pigmentosa

Karine Bigot; Pauline Gondouin; Pierrick Montagne; Romain Benard; Emilie Picard; Yves G Courtois; Ronald BUGGAGE; Thierry Bordet; Francine F Behar-Cohen

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3387. doi:

ARVO Annual Meeting Abstract July 2019

EYS606 for the Treatment of Non-Infectious Uveitis (NIU)

Ronald BUGGAGE; Francine F Behar-Cohen

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3519. doi:

ARVO Annual Meeting Abstract July 2018

Efficacy of EYS606 in Experimental Models of Uveitis

Ronald BUGGAGE; Karine Bigot; Elodie Touchard; Romain Benard; Thierry Bordet; Francine F Behar-Cohen

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1191. doi:

ARVO Annual Meeting Abstract July 2018

A Non-Viral Gene Therapy Approach for Retinitis Pigmentosa

Karine Bigot; Pauline Gondouin; Pierrick Montagne; Romain Benard; Emilie Picard; Yves G Courtois; Ronald Buggage; Thierry Bordet; Francine F Behar-Cohen

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5655. doi:

ARVO Annual Meeting Abstract July 2018

Non-Clinical Safety of Ciliary Muscle Electrotransfection

Thierry Bordet; Karine Bigot; Romain Benard; Jean-Denis Laffitte; Elodie Touchard; Ronald Buggage; Francine F Behar-Cohen

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5679. doi:

ARVO Annual Meeting Abstract June 2017

One Year Results of a Phase I/IIa Study of SAR422459 in Patients with Stargardt Macular Degeneration (SMD)

David J Wilson; Jose Alain Sahel; Richard G Weleber; Laura R Erker; Andreas K Lauer; Tim Stout; Isabelle S Audo; Saddek Mohand-Said; Pierre-Olivier Barale; Laurence Titeux; Ronald BUGGAGE

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):3385. doi:

ARVO Annual Meeting Abstract June 2017

Natural History of Stargardt Disease: Patients’ profile at clinical diagnosis

Catherine Brun-Strang; Andrea PISCOPO; Ronald BUGGAGE; Joseph MILCE; Rahma SELLAMI

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1487. doi:

ARVO Annual Meeting Abstract June 2017

Living with Usher’s syndrome Type 1: Development of a disease impact model from qualitative interviews with patients and their parents

Andrea PISCOPO; Aude ROBOREL de CLIMENS; Catherine Brun-Strang; Ronald BUGGAGE; Carla Dias Barbosa; Naomi KNOBLE

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1355. doi:

ARVO Annual Meeting Abstract June 2017

Understanding the impact of Stargardt disease on patients’ lives: Insights from patients and their parents based on qualitative research

Aude ROBOREL de CLIMENS; Andrea PISCOPO; Catherine Brun-Strang; Ronald BUGGAGE; Carla Dias Barbosa; Béatrice Tugaut

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1356. doi:

ARVO Annual Meeting Abstract June 2017

Safety Profile of the Surgical Procedure for the Administration of Ocular Gene Therapies

Ronald BUGGAGE; Pierre-Olivier Barale; Sarah Ayello-Scheer; Andreas K Lauer; Tim Stout; Isabelle S Audo; Saddek Mohand-Said; Jose Alain Sahel; Paul Yang; Mark E Pennesi; Richard G Weleber; Laurence Titeux; Amel Lahmar; Preethi A Sundaram

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1491. doi:

ARVO Annual Meeting Abstract June 2017

3-Year Interim Safety Profile of Adeno-Associated Virus Serotype 2-soluble Variant of the Vascular Endothelial Growth Factor Receptor Type 1 (AAV2-sFLT01) Administered by Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration

Rafael Varona; Annaig Le-Halpere; Peter A Campochiaro; Jeffrey Heier; Pravin U Dugel; Mark Barsamian; Annie Purvis; Mario Cabrera-Salazar; Cheryl Delacono; Najwa Mostafa; Abraham Scaria; Ronald BUGGAGE

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2321. doi:

ARVO Annual Meeting Abstract June 2017

Natural History of Retinal function and structure in a French cohort of patients with Usher Syndrome Type 1 due to MYO7A Mutations.

Saddek Mohand-Said; Line Azoulay-Sebban; Isabelle S Audo; Céline Chaumette; Céline Devisme; Karine Becker; Emmanuel Gutman; Caroline Segaut-Prevost; Ronald BUGGAGE; Jose Alain Sahel

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4679. doi:

ARVO Annual Meeting Abstract September 2016

Natural History of Early-Onset Stargardt Disease

Ronald BUGGAGE; Andrea Piscopo; Joseph Milce; Perrine Le Calve; Catherine Brun-Strang

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2065. doi:

ARVO Annual Meeting Abstract September 2016

Variability in vitreous haze grading technique using a 9-step logarithmic scale in patients enrolled in the Sarilumab in Non-infectious Uveitis (SARIL-NIU), the Saturn Study

Marc D de Smet; Preethi A Sundaram; Kristine Erickson; Valerie Corp-dit-Genti; Laetitia Vinet; Robert Vitti; Ronald BUGGAGE; Quan Dong Nguyen

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi:

ARVO Annual Meeting Abstract June 2015

Stargardt Disease - A patient’s journey across the world

Ronald BUGGAGE; Majorie Leclerc; Genevieve Bonnelye; Catherine Brun-Strang

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2141. doi:

ARVO Annual Meeting Abstract June 2015

Stargardt Disease: burden from a patient association perspective.

Catherine Brun-Strang; Genevieve Bonnelye; Majorie Leclerc; Ronald BUGGAGE

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2142. doi:

ARVO Annual Meeting Abstract June 2015

Early findings in a Phase I/IIa clinical program for Usher syndrome 1B (USH1B; MIM #276900)

Richard G Weleber; Tim Stout; Andreas K Lauer; Mark E Pennesi; Isabelle S Audo; Saddek Mohand-Said; Pierre-Olivier Barale; Ronald Buggage; Jose Alain Sahel; David J Wilson

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2286. doi:

ARVO Annual Meeting Abstract June 2015

The clinical course of Stargardt disease in a French cohort of patients.

Saddek Mohand-Said; Catherine Brun-Strang; Ronald BUGGAGE; Konstantinos Aliferis; Isabelle S Audo; Caroline Amand; Ieva Sliesoraityte; Alain Stemart; Jose Alain Sahel

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2861. doi:

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

EYS606 for the Treatment of Chronic Non-Infectious Uveitis (NIU): Results from Part 1 of a First-in-Human (EYS606-CT1) study

Repeated plasmid electrotransfection into the ciliary muscle allows for fine-tuning of intraocular protein levels

A promising non-viral gene therapy approach for retinitis pigmentosa

EYS606 for the Treatment of Non-Infectious Uveitis (NIU)

Efficacy of EYS606 in Experimental Models of Uveitis

A Non-Viral Gene Therapy Approach for Retinitis Pigmentosa

Non-Clinical Safety of Ciliary Muscle Electrotransfection

One Year Results of a Phase I/IIa Study of SAR422459 in Patients with Stargardt Macular Degeneration (SMD)

Natural History of Stargardt Disease: Patients’ profile at clinical diagnosis

Living with Usher’s syndrome Type 1: Development of a disease impact model from qualitative interviews with patients and their parents

Understanding the impact of Stargardt disease on patients’ lives: Insights from patients and their parents based on qualitative research

Safety Profile of the Surgical Procedure for the Administration of Ocular Gene Therapies

3-Year Interim Safety Profile of Adeno-Associated Virus Serotype 2-soluble Variant of the Vascular Endothelial Growth Factor Receptor Type 1 (AAV2-sFLT01) Administered by Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration

Natural History of Retinal function and structure in a French cohort of patients with Usher Syndrome Type 1 due to MYO7A Mutations.

Natural History of Early-Onset Stargardt Disease

Variability in vitreous haze grading technique using a 9-step logarithmic scale in patients enrolled in the Sarilumab in Non-infectious Uveitis (SARIL-NIU), the Saturn Study

Stargardt Disease - A patient’s journey across the world

Stargardt Disease: burden from a patient association perspective.

Early findings in a Phase I/IIa clinical program for Usher syndrome 1B (USH1B; MIM #276900)

The clinical course of Stargardt disease in a French cohort of patients.

To View More...

You must be signed into an individual account to use this feature.